NYSE:AMPE

Ampio Pharmaceuticals Stock Forecast

etoro logo Buy AMPE
*Your capital is at risk
$0.183
+0 (+0%)
At Close: Jun 05, 2026
Add AMPE to Watchlist?
Some Reasons Why To Add AMPE:
  • Beat earnings estimates in all of the last 4 quarters
  • +134.3% price growth over the last year
  • +3,421.2% YTD performance

AMPE Performance

FAQ

What is the symbol for Ampio Pharmaceuticals Inc Stock and on which exchange is it traded?
The symbol for Ampio Pharmaceuticals Inc is AMPE and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Ampio Pharmaceuticals Inc Stock?
Ampio Pharmaceuticals Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Ampio Pharmaceuticals Inc Stock?
Ampio Pharmaceuticals Inc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Ampio Pharmaceuticals Inc Stock.

What's the current price of Ampio Pharmaceuticals Inc Stock?
As of the end of day on the Jun 05, 2026, the price of an Ampio Pharmaceuticals Inc (AMPE) share was $0.183.

What is the 52-week high and low for Ampio Pharmaceuticals Inc Stock?
The 52-week high for Ampio Pharmaceuticals Inc Stock is $0.295 and the 52-week low is $0.0001.

What is the market capitalization of Ampio Pharmaceuticals Inc Stock?
As of the Jun 05, 2026, the market capitalization of Ampio Pharmaceuticals Inc is 207.884K.

When is the next earnings date for Ampio Pharmaceuticals Inc?
The upcoming earnings date for Ampio Pharmaceuticals Inc is Aug 11, 2026.
Click to get the best stock tips daily for free!
ABOUT AMPIO PHARMACEUTICALS INC
Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requi...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
4.43% Jun 01
N
NVRI
$19.53
0.87% May 20
RUN
$12.83
15.51% May 06
GLBE
$31.61
4.05% May 05
SAP
$172.39
8.56% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE